D
Dyne Therapeutics, Inc. (DYN)
NMS – Real Time Price. Currency in USD
18.37
-0.09 (-0.49%)
At close: May 12, 2026, 4:00 PM EDT
18.11
-0.26 (-1.39%)
After-hours: May 12, 2026, 5:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
18.37
-0.09 (-0.49%)
At close: May 12, 2026, 4:00 PM EDT
18.11
-0.26 (-1.39%)
After-hours: May 12, 2026, 5:59 PM EDT
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Innovation Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Officer |
| Mr. Daniel Wilson | Senior VP & Head of Legal |
| Mr. James P. Bilotta M.B.A. | Chief Digital & Information Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | dyn-20260511.htm |
| 2026-05-11 | 10-Q | dyn-20260331.htm |
| 2026-04-23 | DEFA14A | 2026_proxy_notice.htm |
| 2026-04-09 | PRE 14A | dyn-20260409.htm |
| 2026-03-27 | S-8 | dyn-20260327.htm |
| 2026-03-02 | S-8 | dyn-20260302.htm |
| 2026-03-02 | 8-K | dyn-20260302.htm |
| 2026-03-02 | 10-K | dyn-20251231.htm |
| 2026-01-12 | 8-K | dyn-20260112.htm |
| 2025-12-23 | 8-K | dyn-20251222.htm |
| Mr. John G. Cox M.B.A. | CEO, President & Director |
| Ms. Debra Feldman | Chief Regulatory Affairs Officer |
| Ms. Johanna Friedl-Naderer | Chief Commercial Officer |
| Ms. Lucia Celona | Chief Human Resource Officer |